Durable Response to Vemurafenib and Cobimetinib for the Treatment of BRAF-Mutated Metastatic Melanoma in Routine Clinical Practice

References

• Guy GP Jr, Thomas CC, Thompson T, Watson M, Massetti GM, Richardson LC. Vital signs: melanoma incidence and mortality trends and projections - United States, 1982–2030. MMWR Morb Mortal Wkly Rep. 2015;64(21):591–596.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Global cancer observatory. Melanoma of skin. Available from: http://gco.iarc.fr/today/data/factsheets/cancers/16-Melanoma-of-skin-fact-sheet.pdf. Accessed June 16, 2020.
   Google Scholar
• National Cancer Institute. Surveillance, epidemiology, and end results program. cancer stat facts: melanoma of skin. Available from: https://seer.cancer.gov/statfacts/html/melan.html. Accessed June 16, 2020.
   Google Scholar
• Cheng L, Lopez-Beltran A, Massari F, MacLennan GT, Montironi R. Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine. Mod Pathol. 2018;31(1):24–38. doi:10.1038/modpathol.2017.104
   PubMed Web of Science ®Google Scholar
• Long GV, Menzies AM, Nagrial AM, et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol. 2011;29(10):1239–1246. doi:10.1200/JCO.2010.32.4327
   PubMed Web of Science ®Google Scholar
• Hugdahl E, Kalvenes MB, Puntervoll HE, Ladstein RG, Akslen LA. BRAF-V600E expression in primary nodular melanoma is associated with aggressive tumour features and reduced survival. Br J Cancer. 2016;114(7):801–808. doi:10.1038/bjc.2016.44
   PubMed Web of Science ®Google Scholar
• Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507–2516. doi:10.1056/NEJMoa1103782
   PubMed Web of Science ®Google Scholar
• Eroglu Z, Ribas A. Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy. Ther Adv Med Oncol. 2016;8(1):48–56. doi:10.1177/1758834015616934
   PubMed Web of Science ®Google Scholar
• Ascierto PA, Dreno B, Larkin J, et al. 5-year outcomes with cobimetinib plus vemurafenib in BRAFV600 mutation-positive advanced melanoma: extended follow-up of the coBRIM study. Clin Cancer Res. 2021. doi:10.1158/1078-0432.CCR-21-0809
   PubMed Web of Science ®Google Scholar
• Dréno B, Ascierto PA, Atkinson V, et al. Health-related quality of life impact of cobimetinib in combination with vemurafenib in patients with advanced or metastatic BRAFV600 mutation-positive melanoma. Br J Cancer. 2018;118(6):777–784. doi:10.1038/bjc.2017.488
   PubMed Web of Science ®Google Scholar
• Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27(36):6199–6206. doi:10.1200/JCO.2009.23.4799
   PubMed Web of Science ®Google Scholar
• Knobel H, Alonso J, Casado JL, et al. Validation of a simplified medication adherence questionnaire in a large cohort of HIV-infected patients: the GEEMA Study. AIDS. 2002;16(4):605–613. doi:10.1097/00002030-200203080-00012
   PubMed Web of Science ®Google Scholar
• Reilly Associates. WPAI scoring. Available from: http://www.reillyassociates.net/WPAI_Scoring.html. Accessed June 16, 2020.
   Google Scholar
• Affleck AG, Stewart AM. The hospital anxiety and depression scale is a screening measure of general distress. Br J Dermatol. 2018;179(2):544. doi:10.1111/bjd.16723
   PubMed Web of Science ®Google Scholar
• Ho AW, Tsao H. Targeted therapies in melanoma: translational research at its finest. J Invest Dermatol. 2015;135(8):1929–1933. doi:10.1038/jid.2015.14
   PubMed Web of Science ®Google Scholar
• Franken MG, Leeneman B, Gheorghe M, Uyl-de Groot CA, Haanen JBAG, van Baal PHM. A systematic literature review and network meta-analysis of effectiveness and safety outcomes in advanced melanoma. Eur J Cancer. 2019;123:58–71. doi:10.1016/j.ejca.2019.08.032
   PubMed Web of Science ®Google Scholar
• Di Guardo L, Cavalieri S, Cimminiello C, et al. Monoinstitutional experience of vemurafenib and cobimetinib for BRAF mutated metastatic melanoma. Ann Oncol. 2016;27(4):89–91. doi:10.1093/annonc/mdw341.08
   Google Scholar
• Drago JZ, Lawrence D, Livingstone E, et al. Clinical experience with combination BRAF/MEK inhibitors for melanoma with brain metastases: a real-life multicenter study. Melanoma Res. 2019;29(1):65–69. doi:10.1097/CMR.0000000000000527
   PubMed Web of Science ®Google Scholar
• Moser JC, Chen D, Hu-Lieskovan S, et al. Real-world survival of patients with advanced BRAF V600 mutated melanoma treated with front-line BRAF/MEK inhibitors, anti-PD-1 antibodies, or nivolumab/ipilimumab. Cancer Med. 2019;8(18):7637–7643. doi:10.1002/cam4.2625
   PubMed Web of Science ®Google Scholar
• Luke JJ, Ghate SR, Kish J, et al. Targeted agents or immuno-oncology therapies as first-line therapy for BRAF-mutated metastatic melanoma: a real-world study. Future Oncol. 2019;15(25):2933–2942. doi:10.2217/fon-2018-0964
   PubMed Web of Science ®Google Scholar
• Cowey CL, Liu FX, Boyd M, Aguilar KM, Krepler C. Real-world treatment patterns and clinical outcomes among patients with advanced melanoma: a retrospective, community oncology-based cohort study (A STROBE-compliant article). Medicine. 2019;98(28):e16328. doi:10.1097/MD.0000000000016328
   PubMed Web of Science ®Google Scholar
• Helgadottir H, Rocha Trocoli Drakensjö I, Girnita A. Personalized medicine in malignant melanoma: towards patient tailored treatment. Front Oncol. 2018;8:202. doi:10.3389/fonc.2018.00202
   PubMed Web of Science ®Google Scholar
• Arnold M, Jiang L, Stefanick ML, et al. Duration of adulthood overweight, obesity, and cancer risk in the women’s health initiative: a longitudinal study from the United States. PLoS Med. 2016;13(8):e1002081. doi:10.1371/journal.pmed.1002081
   PubMed Web of Science ®Google Scholar
• Lennon H, Sperrin M, Badrick E, Renehan AG. The obesity paradox in cancer: a review. Curr Oncol Rep. 2016;18(9):56. doi:10.1007/s11912-016-0539-4
   PubMed Web of Science ®Google Scholar
• McQuade JL, Daniel CR, Hess KR, et al. Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. Lancet Oncol. 2018;19(3):310–322.
   PubMed Web of Science ®Google Scholar
• Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348(17):1625–1638. doi:10.1056/NEJMoa021423
   PubMed Web of Science ®Google Scholar
• Fang S, Wang Y, Dang Y, et al. Association between body mass index, C-reactive protein levels, and melanoma patient outcomes. J Invest Dermatol. 2017;137(8):1792–1795. doi:10.1016/j.jid.2017.04.007
   PubMed Web of Science ®Google Scholar
• Haugh AM, Johnson DB. Management of V600E and V600K BRAF-mutant melanoma. Curr Treat Options Oncol. 2019;20(11):81. doi:10.1007/s11864-019-0680-z
   PubMed Web of Science ®Google Scholar